HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction
Cancer Letters · 2026-02 · 639 · 218219
DOI: 10.1016/j.canlet.2025.218219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2026-02. Verfasst von Fei Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical Univ…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Lung Neoplasms, Glutamine, Carcinoma, Non-Small-Cell Lung. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Medical Center, Jiangsu Cancer Hospital.
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, and EGFR-mutant tumors show limited response to current immunotherapy. The immunosuppressive tumor microenvironment, particularly metabolic constraints on effector T cells, is increasingly recognized as a major barrier to effective anti-tumor responses. HHLA2, a B7 family member frequently elevated in EGFR-mutant NSCLC, has an incompletely defined role in immune escape. In this study, we demonstrate that tumor-derived HHLA2 engages the inhibitory receptor KIR3DL3 on CD8+ T cells, driving T cell exhaustion through metabolic reprogramming of amino acid utilization. HHLA2-KIR3DL3 signaling suppresses glutamine utilization through ERK/MAPK-dependent repression of SLC1A5, SLC38A2, and ADHFE1, key glutamine transporters and metabolic enzymes, thereby inducing metabolic insufficiency and dysfunctional cytokine production in CD8+ T cells, including reduced IFN-γ, TNF-α, and increased IL-10. Disruption of this axis-via HHLA2 deletion or antibody blockade-restored T cell metabolism and effector function, leading to attenuated tumor progression in humanized mouse models. Notably, HHLA2/KIR3DL3 inhibition synergized with EGFR tyrosine kinase inhibitors to enhance anti-tumor immunity and suppress tumor progression. Together, these findings identify HHLA2-KIR3DL3 as a key immunosuppressive pathway in EGFR-mutant NSCLC and may provide a rationale for therapeutic targeting to improve clinical outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
- Department of Thoracic Surgery, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
- Department of Oncology, The Air Force Hospital from Eastern Theater of PLA, Nanjing, China.
- Department of Pathology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
- Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Electronic address: dabaoyan@njmu.edu.cn.
- Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China. Electronic address: shaorongyu@njmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Jiangsu Provincial Medical Center
- Jiangsu Cancer Hospital
Zitieren
APA
Wu, F., Shen, J., Zhao, Z., Chen, Y., Ren, B., Li, M., Yin, R., Zhang, Y., & Yu, S. (2026). HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction. Cancer Letters, 639, 218219. https://doi.org/10.1016/j.canlet.2025.218219
Vancouver
Wu F, Shen J, Zhao Z, Chen Y, Ren B, Li M, et al. HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction. Cancer Letters. 2026;639:218219. doi:10.1016/j.canlet.2025.218219
BibTeX
@article{Wu2026,
author = {Wu, Fei and Shen, Jiannan and Zhao, Zhiting and Chen, Yan and Ren, Binhui and Li, Ming and Yin, Rong and Zhang, Yanyan and Yu, Shaorong},
title = {HHLA2 promotes immune evasion in EGFR-mutant lung cancer by inhibiting CD8+ T cell glutamine metabolism via KIR3DL3 interaction},
journal = {Cancer Letters},
year = {2026},
volume = {639},
pages = {218219},
doi = {10.1016/j.canlet.2025.218219}
}
EUVIMED